Bladder Cancer Molecular Diagnostics Market - Global Outlook and Forecast 2021-2027

April 2021 | 94 pages | ID: BF5AE5F6F31EEN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Bladder Cancer Molecular Diagnostics in Global, including the following market information:

Global Bladder Cancer Molecular Diagnostics Market Revenue, 2016-2021, 2022-2027, ($ millions)

Global top five companies in 2020 (%)

The global Bladder Cancer Molecular Diagnostics market was valued at xx million in 2020 and is projected to reach US$ xx million by 2027, at a CAGR of xx% during the forecast period.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Bladder Cancer Molecular Diagnostics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Bladder Cancer Molecular Diagnostics Market, By Type, 2016-2021, 2022-2027 ($ millions)

Global Bladder Cancer Molecular Diagnostics Market Segment Percentages, By Type, 2020 (%)

• PCR
• FISH
• DNA Sequencing
• Gene Chip

China Bladder Cancer Molecular Diagnostics Market, By Application, 2016-2021, 2022-2027 ($ millions)

China Bladder Cancer Molecular Diagnostics Market Segment Percentages, By Application, 2020 (%)

• Clinical Diagnosis
• Drug Screening
• Research

Global Bladder Cancer Molecular Diagnostics Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)

Global Bladder Cancer Molecular Diagnostics Market Segment Percentages, By Region and Country, 2020 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Total Bladder Cancer Molecular Diagnostics Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)

Total Bladder Cancer Molecular Diagnostics Market Competitors Revenues Share in Global, by Players 2020 (%)

Further, the report presents profiles of competitors in the market, including the following:

• Genetech
• Gpmedical
• Gene+
• DMDbiomed
• Annoroad
• Topgen
• Geneis
• Unitedgene
• Inmedi

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Bladder Cancer Molecular Diagnostics Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Bladder Cancer Molecular Diagnostics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL BLADDER CANCER MOLECULAR DIAGNOSTICS OVERALL MARKET SIZE

2.1 Global Bladder Cancer Molecular Diagnostics Market Size: 2021 VS 2027
2.2 Global Bladder Cancer Molecular Diagnostics Market Size, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Bladder Cancer Molecular Diagnostics Players in Global Market
3.2 Top Global Bladder Cancer Molecular Diagnostics Companies Ranked by Revenue
3.3 Global Bladder Cancer Molecular Diagnostics Revenue by Companies
3.4 Top 3 and Top 5 Bladder Cancer Molecular Diagnostics Companies in Global Market, by Revenue in 2020
3.5 Global Companies Bladder Cancer Molecular Diagnostics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Bladder Cancer Molecular Diagnostics Players in Global Market
  3.6.1 List of Global Tier 1 Bladder Cancer Molecular Diagnostics Companies
  3.6.2 List of Global Tier 2 and Tier 3 Bladder Cancer Molecular Diagnostics Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 By Type - Global Bladder Cancer Molecular Diagnostics Market Size Markets, 2021 & 2027
  4.1.2 PCR
  4.1.3 FISH
  4.1.4 DNA Sequencing
  4.1.5 Gene Chip
4.2 By Type - Global Bladder Cancer Molecular Diagnostics Revenue & Forecasts
  4.2.1 By Type - Global Bladder Cancer Molecular Diagnostics Revenue, 2016-2021
  4.2.2 By Type - Global Bladder Cancer Molecular Diagnostics Revenue, 2022-2027
  4.2.3 By Type - Global Bladder Cancer Molecular Diagnostics Revenue Market Share, 2016-2027

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Bladder Cancer Molecular Diagnostics Market Size, 2021 & 2027
  5.1.2 Clinical Diagnosis
  5.1.3 Drug Screening
  5.1.4 Research
5.2 By Application - Global Bladder Cancer Molecular Diagnostics Revenue & Forecasts
  5.2.1 By Application - Global Bladder Cancer Molecular Diagnostics Revenue, 2016-2021
  5.2.2 By Application - Global Bladder Cancer Molecular Diagnostics Revenue, 2022-2027
  5.2.3 By Application - Global Bladder Cancer Molecular Diagnostics Revenue Market Share, 2016-2027

6 SIGHTS BY REGION

6.1 By Region - Global Bladder Cancer Molecular Diagnostics Market Size, 2021 & 2027
6.2 By Region - Global Bladder Cancer Molecular Diagnostics Revenue & Forecasts
  6.2.1 By Region - Global Bladder Cancer Molecular Diagnostics Revenue, 2016-2021
  6.2.2 By Region - Global Bladder Cancer Molecular Diagnostics Revenue, 2022-2027
  6.2.3 By Region - Global Bladder Cancer Molecular Diagnostics Revenue Market Share, 2016-2027
6.3 North America
  6.3.1 By Country - North America Bladder Cancer Molecular Diagnostics Revenue, 2016-2027
  6.3.2 US Bladder Cancer Molecular Diagnostics Market Size, 2016-2027
  6.3.3 Canada Bladder Cancer Molecular Diagnostics Market Size, 2016-2027
  6.3.4 Mexico Bladder Cancer Molecular Diagnostics Market Size, 2016-2027
6.4 Europe
  6.4.1 By Country - Europe Bladder Cancer Molecular Diagnostics Revenue, 2016-2027
  6.4.2 Germany Bladder Cancer Molecular Diagnostics Market Size, 2016-2027
  6.4.3 France Bladder Cancer Molecular Diagnostics Market Size, 2016-2027
  6.4.4 U.K. Bladder Cancer Molecular Diagnostics Market Size, 2016-2027
  6.4.5 Italy Bladder Cancer Molecular Diagnostics Market Size, 2016-2027
  6.4.6 Russia Bladder Cancer Molecular Diagnostics Market Size, 2016-2027
  6.4.7 Nordic Countries Bladder Cancer Molecular Diagnostics Market Size, 2016-2027
  6.4.8 Benelux Bladder Cancer Molecular Diagnostics Market Size, 2016-2027
6.5 Asia
  6.5.1 By Region - Asia Bladder Cancer Molecular Diagnostics Revenue, 2016-2027
  6.5.2 China Bladder Cancer Molecular Diagnostics Market Size, 2016-2027
  6.5.3 Japan Bladder Cancer Molecular Diagnostics Market Size, 2016-2027
  6.5.4 South Korea Bladder Cancer Molecular Diagnostics Market Size, 2016-2027
  6.5.5 Southeast Asia Bladder Cancer Molecular Diagnostics Market Size, 2016-2027
  6.5.6 India Bladder Cancer Molecular Diagnostics Market Size, 2016-2027
6.6 South America
  6.6.1 By Country - South America Bladder Cancer Molecular Diagnostics Revenue, 2016-2027
  6.6.2 Brazil Bladder Cancer Molecular Diagnostics Market Size, 2016-2027
  6.6.3 Argentina Bladder Cancer Molecular Diagnostics Market Size, 2016-2027
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Bladder Cancer Molecular Diagnostics Revenue, 2016-2027
  6.7.2 Turkey Bladder Cancer Molecular Diagnostics Market Size, 2016-2027
  6.7.3 Israel Bladder Cancer Molecular Diagnostics Market Size, 2016-2027
  6.7.4 Saudi Arabia Bladder Cancer Molecular Diagnostics Market Size, 2016-2027
  6.7.5 UAE Bladder Cancer Molecular Diagnostics Market Size, 2016-2027

7 PLAYERS PROFILES

7.1 Genetech
  7.1.1 Genetech Corporate Summary
  7.1.2 Genetech Business Overview
  7.1.3 Genetech Bladder Cancer Molecular Diagnostics Major Product Offerings
  7.1.4 Genetech Bladder Cancer Molecular Diagnostics Revenue in Global (2016-2021)
  7.1.5 Genetech Key News
7.2 Gpmedical
  7.2.1 Gpmedical Corporate Summary
  7.2.2 Gpmedical Business Overview
  7.2.3 Gpmedical Bladder Cancer Molecular Diagnostics Major Product Offerings
  7.2.4 Gpmedical Bladder Cancer Molecular Diagnostics Revenue in Global (2016-2021)
  7.2.5 Gpmedical Key News
7.3 Gene+
  7.3.1 Gene+ Corporate Summary
  7.3.2 Gene+ Business Overview
  7.3.3 Gene+ Bladder Cancer Molecular Diagnostics Major Product Offerings
  7.3.4 Gene+ Bladder Cancer Molecular Diagnostics Revenue in Global (2016-2021)
  7.3.5 Gene+ Key News
7.4 DMDbiomed
  7.4.1 DMDbiomed Corporate Summary
  7.4.2 DMDbiomed Business Overview
  7.4.3 DMDbiomed Bladder Cancer Molecular Diagnostics Major Product Offerings
  7.4.4 DMDbiomed Bladder Cancer Molecular Diagnostics Revenue in Global (2016-2021)
  7.4.5 DMDbiomed Key News
7.5 Annoroad
  7.5.1 Annoroad Corporate Summary
  7.5.2 Annoroad Business Overview
  7.5.3 Annoroad Bladder Cancer Molecular Diagnostics Major Product Offerings
  7.5.4 Annoroad Bladder Cancer Molecular Diagnostics Revenue in Global (2016-2021)
  7.5.5 Annoroad Key News
7.6 Topgen
  7.6.1 Topgen Corporate Summary
  7.6.2 Topgen Business Overview
  7.6.3 Topgen Bladder Cancer Molecular Diagnostics Major Product Offerings
  7.6.4 Topgen Bladder Cancer Molecular Diagnostics Revenue in Global (2016-2021)
  7.6.5 Topgen Key News
7.7 Geneis
  7.7.1 Geneis Corporate Summary
  7.7.2 Geneis Business Overview
  7.7.3 Geneis Bladder Cancer Molecular Diagnostics Major Product Offerings
  7.4.4 Geneis Bladder Cancer Molecular Diagnostics Revenue in Global (2016-2021)
  7.7.5 Geneis Key News
7.8 Unitedgene
  7.8.1 Unitedgene Corporate Summary
  7.8.2 Unitedgene Business Overview
  7.8.3 Unitedgene Bladder Cancer Molecular Diagnostics Major Product Offerings
  7.8.4 Unitedgene Bladder Cancer Molecular Diagnostics Revenue in Global (2016-2021)
  7.8.5 Unitedgene Key News
7.9 Inmedi
  7.9.1 Inmedi Corporate Summary
  7.9.2 Inmedi Business Overview
  7.9.3 Inmedi Bladder Cancer Molecular Diagnostics Major Product Offerings
  7.9.4 Inmedi Bladder Cancer Molecular Diagnostics Revenue in Global (2016-2021)
  7.9.5 Inmedi Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Bladder Cancer Molecular Diagnostics Market Opportunities & Trends in Global Market
Table 2. Bladder Cancer Molecular Diagnostics Market Drivers in Global Market
Table 3. Bladder Cancer Molecular Diagnostics Market Restraints in Global Market
Table 4. Key Players of Bladder Cancer Molecular Diagnostics in Global Market
Table 5. Top Bladder Cancer Molecular Diagnostics Players in Global Market, Ranking by Revenue (2019)
Table 6. Global Bladder Cancer Molecular Diagnostics Revenue by Companies, (US$, Mn), 2016-2021
Table 7. Global Bladder Cancer Molecular Diagnostics Revenue Share by Companies, 2016-2021
Table 8. Global Companies Bladder Cancer Molecular Diagnostics Product Type
Table 9. List of Global Tier 1 Bladder Cancer Molecular Diagnostics Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Bladder Cancer Molecular Diagnostics Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type – Global Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2021 VS 2027
Table 12. By Type - Bladder Cancer Molecular Diagnostics Revenue in Global (US$, Mn), 2016-2021
Table 13. By Type - Bladder Cancer Molecular Diagnostics Revenue in Global (US$, Mn), 2022-2027
Table 14. By Application – Global Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2021 VS 2027
Table 15. By Application - Bladder Cancer Molecular Diagnostics Revenue in Global (US$, Mn), 2016-2021
Table 16. By Application - Bladder Cancer Molecular Diagnostics Revenue in Global (US$, Mn), 2022-2027
Table 17. By Region – Global Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2021 VS 2027
Table 18. By Region - Global Bladder Cancer Molecular Diagnostics Revenue (US$, Mn), 2016-2021
Table 19. By Region - Global Bladder Cancer Molecular Diagnostics Revenue (US$, Mn), 2022-2027
Table 20. By Country - North America Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2016-2021
Table 21. By Country - North America Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2022-2027
Table 22. By Country - Europe Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2016-2021
Table 23. By Country - Europe Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2022-2027
Table 24. By Region - Asia Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2016-2021
Table 25. By Region - Asia Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2022-2027
Table 26. By Country - South America Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2016-2021
Table 27. By Country - South America Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2022-2027
Table 28. By Country - Middle East & Africa Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2016-2021
Table 29. By Country - Middle East & Africa Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2022-2027
Table 30. Genetech Corporate Summary
Table 31. Genetech Bladder Cancer Molecular Diagnostics Product Offerings
Table 32. Genetech Bladder Cancer Molecular Diagnostics Revenue (US$, Mn), (2016-2021)
Table 33. Gpmedical Corporate Summary
Table 34. Gpmedical Bladder Cancer Molecular Diagnostics Product Offerings
Table 35. Gpmedical Bladder Cancer Molecular Diagnostics Revenue (US$, Mn), (2016-2021)
Table 36. Gene+ Corporate Summary
Table 37. Gene+ Bladder Cancer Molecular Diagnostics Product Offerings
Table 38. Gene+ Bladder Cancer Molecular Diagnostics Revenue (US$, Mn), (2016-2021)
Table 39. DMDbiomed Corporate Summary
Table 40. DMDbiomed Bladder Cancer Molecular Diagnostics Product Offerings
Table 41. DMDbiomed Bladder Cancer Molecular Diagnostics Revenue (US$, Mn), (2016-2021)
Table 42. Annoroad Corporate Summary
Table 43. Annoroad Bladder Cancer Molecular Diagnostics Product Offerings
Table 44. Annoroad Bladder Cancer Molecular Diagnostics Revenue (US$, Mn), (2016-2021)
Table 45. Topgen Corporate Summary
Table 46. Topgen Bladder Cancer Molecular Diagnostics Product Offerings
Table 47. Topgen Bladder Cancer Molecular Diagnostics Revenue (US$, Mn), (2016-2021)
Table 48. Geneis Corporate Summary
Table 49. Geneis Bladder Cancer Molecular Diagnostics Product Offerings
Table 50. Geneis Bladder Cancer Molecular Diagnostics Revenue (US$, Mn), (2016-2021)
Table 51. Unitedgene Corporate Summary
Table 52. Unitedgene Bladder Cancer Molecular Diagnostics Product Offerings
Table 53. Unitedgene Bladder Cancer Molecular Diagnostics Revenue (US$, Mn), (2016-2021)
Table 54. Inmedi Corporate Summary
Table 55. Inmedi Bladder Cancer Molecular Diagnostics Product Offerings
Table 56. Inmedi Bladder Cancer Molecular Diagnostics Revenue (US$, Mn), (2016-2021)

List Of Figures

LIST OF FIGURES

Figure 1. Bladder Cancer Molecular Diagnostics Segment by Type
Figure 2. Bladder Cancer Molecular Diagnostics Segment by Application
Figure 3. Global Bladder Cancer Molecular Diagnostics Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global Bladder Cancer Molecular Diagnostics Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. Global Bladder Cancer Molecular Diagnostics Revenue, 2016-2027 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Bladder Cancer Molecular Diagnostics Revenue in 2020
Figure 8. By Type - Global Bladder Cancer Molecular Diagnostics Revenue Market Share, 2016-2027
Figure 9. By Application - Global Bladder Cancer Molecular Diagnostics Revenue Market Share, 2016-2027
Figure 10. By Region - Global Bladder Cancer Molecular Diagnostics Revenue Market Share, 2016-2027
Figure 11. By Country - North America Bladder Cancer Molecular Diagnostics Revenue Market Share, 2016-2027
Figure 12. US Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2016-2027
Figure 13. Canada Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2016-2027
Figure 14. Mexico Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2016-2027
Figure 15. By Country - Europe Bladder Cancer Molecular Diagnostics Revenue Market Share, 2016-2027
Figure 16. Germany Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2016-2027
Figure 17. France Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2016-2027
Figure 18. U.K. Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2016-2027
Figure 19. Italy Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2016-2027
Figure 20. Russia Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2016-2027
Figure 21. Nordic Countries Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2016-2027
Figure 22. Benelux Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2016-2027
Figure 23. By Region - Asia Bladder Cancer Molecular Diagnostics Revenue Market Share, 2016-2027
Figure 24. China Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2016-2027
Figure 25. Japan Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2016-2027
Figure 26. South Korea Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2016-2027
Figure 27. Southeast Asia Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2016-2027
Figure 28. India Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2016-2027
Figure 29. By Country - South America Bladder Cancer Molecular Diagnostics Revenue Market Share, 2016-2027
Figure 30. Brazil Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2016-2027
Figure 31. Argentina Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2016-2027
Figure 32. By Country - Middle East & Africa Bladder Cancer Molecular Diagnostics Revenue Market Share, 2016-2027
Figure 33. Turkey Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2016-2027
Figure 34. Israel Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2016-2027
Figure 35. Saudi Arabia Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2016-2027
Figure 36. UAE Bladder Cancer Molecular Diagnostics Revenue, (US$, Mn), 2016-2027
Figure 37. Genetech Bladder Cancer Molecular Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 38. Gpmedical Bladder Cancer Molecular Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 39. Gene+ Bladder Cancer Molecular Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 40. DMDbiomed Bladder Cancer Molecular Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 41. Annoroad Bladder Cancer Molecular Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 42. Topgen Bladder Cancer Molecular Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 43. Geneis Bladder Cancer Molecular Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 44. Unitedgene Bladder Cancer Molecular Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)